These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 38876305)
1. A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2. Dederer V; Sanz Murillo M; Karasmanis EP; Hatch KS; Chatterjee D; Preuss F; Abdul Azeez KR; Nguyen LV; Galicia C; Dreier B; Plückthun A; Versees W; Mathea S; Leschziner AE; Reck-Peterson SL; Knapp S J Biol Chem; 2024 Jul; 300(7):107469. PubMed ID: 38876305 [TBL] [Abstract][Full Text] [Related]
2. Crystal structure of the WD40 domain dimer of LRRK2. Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421 [TBL] [Abstract][Full Text] [Related]
4. The In Situ Structure of Parkinson's Disease-Linked LRRK2. Watanabe R; Buschauer R; Böhning J; Audagnotto M; Lasker K; Lu TW; Boassa D; Taylor S; Villa E Cell; 2020 Sep; 182(6):1508-1518.e16. PubMed ID: 32783917 [TBL] [Abstract][Full Text] [Related]
5. Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts. Guaitoli G; Raimondi F; Gilsbach BK; Gómez-Llorente Y; Deyaert E; Renzi F; Li X; Schaffner A; Jagtap PK; Boldt K; von Zweydorf F; Gotthardt K; Lorimer DD; Yue Z; Burgin A; Janjic N; Sattler M; Versées W; Ueffing M; Ubarretxena-Belandia I; Kortholt A; Gloeckner CJ Proc Natl Acad Sci U S A; 2016 Jul; 113(30):E4357-66. PubMed ID: 27357661 [TBL] [Abstract][Full Text] [Related]
6. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203 [TBL] [Abstract][Full Text] [Related]
7. Structure of LRRK2 in Parkinson's disease and model for microtubule interaction. Deniston CK; Salogiannis J; Mathea S; Snead DM; Lahiri I; Matyszewski M; Donosa O; Watanabe R; Böhning J; Shiau AK; Knapp S; Villa E; Reck-Peterson SL; Leschziner AE Nature; 2020 Dec; 588(7837):344-349. PubMed ID: 32814344 [TBL] [Abstract][Full Text] [Related]
8. Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2. Singh RK; Soliman A; Guaitoli G; Störmer E; von Zweydorf F; Dal Maso T; Oun A; Van Rillaer L; Schmidt SH; Chatterjee D; David JA; Pardon E; Schwartz TU; Knapp S; Kennedy EJ; Steyaert J; Herberg FW; Kortholt A; Gloeckner CJ; Versées W Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217606 [TBL] [Abstract][Full Text] [Related]
9. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2. Park Y; Liao J; Hoang QQ Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518 [TBL] [Abstract][Full Text] [Related]
11. LRRK2 and Rab GTPases. Pfeffer SR Biochem Soc Trans; 2018 Dec; 46(6):1707-1712. PubMed ID: 30467121 [TBL] [Abstract][Full Text] [Related]
12. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A. Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905 [TBL] [Abstract][Full Text] [Related]
15. Development of phospho-specific Rab protein antibodies to monitor Lis P; Burel S; Steger M; Mann M; Brown F; Diez F; Tonelli F; Holton JL; Ho PW; Ho SL; Chou MY; Polinski NK; Martinez TN; Davies P; Alessi DR Biochem J; 2018 Jan; 475(1):1-22. PubMed ID: 29127256 [TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and pathophysiological properties of newly discovered LRRK2 variants associated with Parkinson's disease. Tezuka T; Ishiguro M; Taniguchi D; Osogaguchi E; Shiba-Fukushima K; Ogata J; Ishii R; Ikeda A; Li Y; Yoshino H; Matsui T; Kaida K; Funayama M; Nishioka K; Kumazawa F; Matsubara T; Tsuda H; Saito Y; Murayama S; Imai Y; Hattori N Neurobiol Dis; 2024 Sep; 199():106571. PubMed ID: 38901781 [TBL] [Abstract][Full Text] [Related]
18. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function. Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688 [TBL] [Abstract][Full Text] [Related]
19. Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules. Snead DM; Matyszewski M; Dickey AM; Lin YX; Leschziner AE; Reck-Peterson SL Nat Struct Mol Biol; 2022 Dec; 29(12):1196-1207. PubMed ID: 36510024 [TBL] [Abstract][Full Text] [Related]
20. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties. Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]